Predictors of treatment switching in the Big Multiple Sclerosis Data Network

- Spelman, Tim, Magyari, Melinda, Hyde, Robert, Duquette, Pierre, Lechner-Scott, Jeannette, Sajedi, Seyed Aidin, Lalive, Patrice, Shaygannejad, Vahid, Ozakbas, Serkan, Eichau, Sara, Alroughani, Raed, Terzi, Murat, Butzkueven, Helmut, Girard, Marc, Kalincik, T, Grand'Maison, F, Skibina, O, Khoury, SJ, Yamout, B, Sa, MJ, Gerlach, O, Blanco, Y, Karabudak, R, Van Der Walt, Anneke, Oreja-Guevara, C, Altintas, A, Hughes, S, Mccombe, P, Ampapa, R, de Gans, K, Mcguigan, C, Soysal, A, Prevost, J, John, N, Vukusic, Sandra, Inshasi, J, Stawiarz, L, Manouchehrinia, A, Forsberg, L, Sellebjerg, F, Glaser, A, Pontieri, L, Joensen, H, Rasmussen, PV, Sejbaek, T, Trojano, Maria, Poulsen, MB, Christensen, JR, Kant, M, Stilund, M, Mathiesen, H, Hillert, J, Iaffaldano, Pietro, Horáková, Dana, Drahota, Jiří, Pellegrini, Fabio

Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis

- Spelman, T., Mekhael, L., Grammond, P., Barnett, M., Lechner-Scott, J., Alroughani, R., Trojano, M., Lugaresi, A., Granella, F., Pucci, E., Vucic, S., Burke, T., Butzkueven, H., Hodgkinson, S., Havrdova, E., Horakova, D., Duquette, P., Izquierdo, G., Grand'Maison, F.